Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Neoplasms 2Stage IA Pancreatic Adenocarcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Immunotherapy 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Esophageal Neoplasms 1Efficacy and Safety 1Drug-Related Side Effects and Adverse Reactions 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extrapancreatic Neuroendocrine Tumor × Tegafur × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡